Company Description
Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States.
It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.
The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies.
The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth.
In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.
Daré Bioscience, Inc. is headquartered in San Diego, California.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Sabrina Johnson |
Contact Details
Address: 3655 Nobel Drive, Suite 260 San Diego, California 92122 United States | |
| Phone | 858 926 7655 |
| Website | darebioscience.com |
Stock Details
| Ticker Symbol | DARE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401914 |
| CUSIP Number | 23666P101 |
| ISIN Number | US23666P1012 |
| Employer ID | 20-4139823 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sabrina Martucci Johnson | Chief Executive Officer, President, Principal Financial Officer, Secretary and Director |
| Mark Walters | Vice President of Operations |
| MarDee J. Haring-Layton | Chief Accounting Officer |
| Dr. David Friend | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 26, 2024 | EFFECT | Notice of Effectiveness |
| Nov 26, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | D | Notice of Exempt Offering of Securities |
| Nov 19, 2024 | UPLOAD | Filing |
| Nov 15, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 14, 2024 | 8-K | Current Report |